{"id":2361,"date":"2026-01-20T17:44:30","date_gmt":"2026-01-20T17:44:30","guid":{"rendered":"https:\/\/malaysian-business.com\/wptest\/2026\/01\/20\/novo-nordisks-launches-victoza\/"},"modified":"2026-01-23T18:00:40","modified_gmt":"2026-01-23T18:00:40","slug":"novo-nordisks-launches-victoza","status":"publish","type":"post","link":"https:\/\/malaysian-business.com\/portal\/2026\/01\/20\/novo-nordisks-launches-victoza\/","title":{"rendered":"Novo Nordisk\u2019s Launches Victoza\u00ae"},"content":{"rendered":"

Recently, Novo Nordisk\u2019s diabetes treatment Victoza<\/span>\u00ae<\/span> (liraglutide) is clinically proven to be kinder on diabetes patients\u2019 hearts and kidneys, offering them a better future.<\/span><\/p>\n

Victoza<\/span>\u00ae<\/span> is the only glucagon-like peptide-1 (GLP-1) agonist that is indicated to reduce the risk of three major adverse cardiovascular events, non-fatal heart attack, non-fatal stroke and cardiovascular deaths.<\/span><\/p>\n

Victoza<\/span>\u00ae<\/span> was approved in Malaysia for a new indication to reduce the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke in type 2 diabetes patients, the only GLP-1 treatment to be indicated for this.<\/span><\/p>\n

This indication was approved after the landmark Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial conducted with more than 9,300 patients with type 2 diabetes, showed that Victoza<\/span>\u00ae<\/span> significantly reduced the risk of a three-component endpoint consisting of cardiovascular death, non-fatal heart attack or non-fatal stroke by 13 per cent versus placebo, with an absolute risk reduction of 1.9 per cent.<\/span><\/p>\n

Furthermore, for renal microvascular events, Victoza<\/span>\u00ae<\/span> was proven to lower the risk of these outcomes as compared to patients who received placebo.<\/span><\/p>\n

It was also found that there was no dose adjustment required for Victoza<\/span>\u00ae<\/span> for patients with mild, moderate or severe renal impairment.<\/span><\/p>\n

Victoza\u00ae is an analogue GLP-1 that has been indicated for treatment of adults with type 2 diabetes, it is clinically proven to lower blood glucose levels and been associated with slight reductions in weight and blood pressure.<\/span><\/p>\n

\u201cAlarmingly, there is an increasing number of young patients being diagnosed with diabetes, this is concerning as the younger the patients, the higher the risk of complications developing earlier. <\/span><\/p>\n

\u201cPatients with type 2 diabetes can develop severe cardiovascular diseases such as heart attack, heart failure and stroke, and diabetic patients are two to six times more likely to die from a cardiovascular complication. <\/span><\/p>\n

\u201cAdditionally, diabetes is also the leading cause of kidney disease, with about one out of four adults with diabetes, developing renal impairment,\u201d said Hospital Putrajaya consultant endocrinologist, Dr Zanariah Hussein. \u00a0<\/span><\/p>\n

\u201cPatients with type 2 diabetes are often not fully aware of the danger of developing heart diseases, complications like coronary heart disease and heart failure develop earlier in type 2 diabetes patient due to plaque build-up that blocks the arteries, thus reducing blood flow to the heart and potentially causing a heart attack. <\/span><\/p>\n

\u201cWithout the right treatments, it would be difficult to manage these two diseases effectively,\u201d said Institut Jantung Negara consultant cardiologist, Datuk Seri Dr Azhari bin Rosman.<\/span><\/p>\n

\u201cMalaysians with type 2 diabetes can now look towards a new lease of life with the new indication of Victoza<\/span>\u00ae<\/span> in the market.<\/span><\/p>\n

\u201cAs a healthcare professional, this is a welcomed treatment as it not only gives patients better control of diabetes, but also prevents potentially fatal cardiovascular events like heart attacks,\u201d said consultant endocrinologist, Dr Chan Siew Pheng.<\/span><\/p>\n

\u201cAt Novo Nordisk, helping diabetes patients overcome their challenges has been part of our heritage for more than 90 years, and we intend to continue delivering on this commitment.<\/span><\/p>\n

\u201cVictoza<\/span>\u00ae<\/span> is an established trusted treatment for type 2 diabetes, the new indication of reducing associated cardiovascular events is the next step in enhancing the health and quality of life of Malaysian patients.<\/span><\/p>\n

\u201cWe hope to continue innovating new treatment options that will address critical aspects of diabetes care beyond glucose lowering,\u201d said Novo Nordisk Pharma (M) Sdn Bhd vice president & general manager (Malaysia, Singapore, Brunei, Sri Lanka and Maldives), Richard Abela.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Recently, Novo Nordisk\u2019s diabetes treatment Victoza\u00ae (liraglutide) is clinically proven to be kinder on diabetes patients\u2019 hearts and kidneys, offering them a better future. Victoza\u00ae is the only glucagon-like peptide-1 (GLP-1) agonist that is indicated to reduce the risk of three major adverse cardiovascular events, non-fatal heart attack, non-fatal stroke and cardiovascular deaths. Victoza\u00ae was […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-2361","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/malaysian-business.com\/portal\/wp-json\/wp\/v2\/posts\/2361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/malaysian-business.com\/portal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/malaysian-business.com\/portal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/malaysian-business.com\/portal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/malaysian-business.com\/portal\/wp-json\/wp\/v2\/comments?post=2361"}],"version-history":[{"count":1,"href":"https:\/\/malaysian-business.com\/portal\/wp-json\/wp\/v2\/posts\/2361\/revisions"}],"predecessor-version":[{"id":4251,"href":"https:\/\/malaysian-business.com\/portal\/wp-json\/wp\/v2\/posts\/2361\/revisions\/4251"}],"wp:attachment":[{"href":"https:\/\/malaysian-business.com\/portal\/wp-json\/wp\/v2\/media?parent=2361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/malaysian-business.com\/portal\/wp-json\/wp\/v2\/categories?post=2361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/malaysian-business.com\/portal\/wp-json\/wp\/v2\/tags?post=2361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}